Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2017

View Archived Issues

Phase II data from IPROTECT1 trial presented for VAC-3S anti-HIV1 vaccine

AbbVie presents key events from the second quarter 2017

Astellas recaps pipeline highlights of first quarter of fiscal 2017

IMMU-132 induces durable responses in heavily pretreated patients with metastatic NSCLC

Shionogi reviews key regulatory and pipeline events of first quarter of fiscal 2017

FDA approves Nityr tablets for treatment of hereditary tyrosinemia type 1

Phase III trial shows HIV suppression with bictegravir/emtricitabine/tenofovir coformulation

Muscarinic M1 receptor modulator from Suven has no cholinergic side effects in animal models

First patient treated in phase II trial of Acceleron Pharma's ACE-083

Aptinyx begins phase II studies of NYX-2925

French researchers patent compounds for treating cancer

FDA awards fast track designation to oral pritelivir for HSV in immunocompromised adults

Celgene identifies antiproliferative compounds for AML

Arcus Biosciences divulges CD73 inhibitors

Teva presents laquinimod prodrugs for multiple sclerosis

Soluble guanylate cyclase activators presented by Bayer

Rockefeller University divulges FXIIa inhibitors

Lundbeck joins large study of genetic causes of MDD and bipolar depression

Wakamoto begins phase II study of WP-1303 in Japan

FDA approves Opdivo for MSI-H and dMMR metastatic colorectal cancer

Integrated BioTherapeutics obtains funding to develop pan-ebolavirus vaccine

Cellectar Biosciences enters collaboration with Avicenna Oncology

FDA grants priority review to acalabrutinib NDA

NeuroDerm to hold extraordinary shareholder meeting regarding acquisition by Mitsubishi Tanabe

Amygdala Neurosciences initiates phase Ib study of ALDH2 inhibitor

TG Therapeutics, FDA reach agreement on phase III studies of TG-1101

FDA approves Idhifa for R/R AML with IDH2 mutation

FDA approves Epclusa for use in hepatitis C patients co-infected with HIV